Peramivir Patent Expiration
Peramivir is Used for treating acute uncomplicated influenza in patients 6 months and older. It was first introduced by Biocryst Pharmaceuticals Inc
Peramivir Patents
Given below is the list of patents protecting Peramivir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rapivab | US8778997 | Antiviral treatments | May 07, 2027 | Biocryst |
| Rapivab | US10391075 | Antiviral treatments | Feb 12, 2027 | Biocryst |
| Rapivab | US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec 16, 2023
(Expired) | Biocryst |
| Rapivab | US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov 05, 2019
(Expired) | Biocryst |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Peramivir's patents.
Latest Legal Activities on Peramivir's Patents
Given below is the list recent legal activities going on the following patents of Peramivir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10391075 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Dec, 2021 | US8778997 |
| Recordation of Patent Grant Mailed Critical | 27 Aug, 2019 | US10391075 |
| Patent Issue Date Used in PTA Calculation Critical | 27 Aug, 2019 | US10391075 |
| Email Notification Critical | 08 Aug, 2019 | US10391075 |
| Issue Notification Mailed Critical | 07 Aug, 2019 | US10391075 |
| Dispatch to FDC | 29 Jul, 2019 | US10391075 |
| Application Is Considered Ready for Issue Critical | 19 Jul, 2019 | US10391075 |
| Issue Fee Payment Verified Critical | 12 Jul, 2019 | US10391075 |
| Issue Fee Payment Received Critical | 12 Jul, 2019 | US10391075 |
Peramivir's Family Patents
